Pinnacle Associates’s Intellia Therapeutics NTLA Stock Holding History

Pinnacle Associates’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.74M	Buy	339,024 +193,512	+133%	+$2.71M	0.06%	252
2026 Q1	$1.87M	Sell	145,512 -3,719	-2%	-$47.4K	0.02%	406
2025 Q4	$1.34M	Sell	149,231 -14,479	-9%	-$199K	0.02%	470
2025 Q3	$2.83M	Sell	163,710 -5,640	-3%	-$69.5K	0.04%	342
2025 Q2	$1.59M	Sell	169,350 -45,470	-21%	-$373K	0.02%	421
2025 Q1	$1.53M	Sell	214,820 -5,352	-2%	-$54.1K	0.02%	416
2024 Q4	$2.57M	Buy	+220,172	New	+$3.44M	0.03%	339
2024 Q3	–	Sell	-251,078	Closed	-$5.62M	–	833
2024 Q2	$5.62M	Sell	251,078 -4,638	-2%	-$110K	0.09%	232
2024 Q1	$7.03M	Buy	+255,716	New	+$7.1M	0.11%	202

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Pinnacle Associates's NTLA Position: Q2 2026 in Review

Pinnacle Associates increased its Intellia Therapeutics (NTLA) stake by 133% in Q2 2026, buying an estimated $2.71M and bringing the position to 339,024 shares worth $5.74M. The position accounts for 0.06% of the portfolio, ranked #252.

Pinnacle Associates first reported a position in NTLA in Q1 2024 and has held it in 9 quarters since. The position peaked at $7.03M in Q1 2024. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Pinnacle Associates held 339,024 shares of Intellia Therapeutics worth $5.74M as of Q2 2026.
Pinnacle Associates bought 193,512 Intellia Therapeutics shares in Q2 2026, an estimated $2.71M.
Intellia Therapeutics made up 0.06% of Pinnacle Associates's portfolio in Q2 2026, its #252 holding.
Pinnacle Associates first reported a position in Intellia Therapeutics in Q1 2024 and has held it in 9 quarters since.
Pinnacle Associates's Intellia Therapeutics position peaked at $7.03M in Q1 2024.
329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Pinnacle Associates's 13F filing for Q2 2026, filed 3 Aug 2026.